Patient Portal

Vivek Kumar Arora, MD, PhD

Assistant Professor, Medicine
Division of Medical Oncology

Specialty Areas

Medical Oncology
Genitourinary Oncology
Prostate Cancer
Bladder Cancer

Board Certifications

Internal Medicine
Medical Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Genitourinary oncology, prostate cancer, bladder cancer

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Siteman Cancer Center - South County

5225 MidAmerica Plaza
St. Louis, MO 63129

Office Phone: 314-286-2500

Education

Education

Research Fellowship, Medical Oncology: Memorial Sloan-Kettering Cancer Center, New York, NY 2014
Fellowship, Medical Oncology: Memorial Sloan-Kettering Cancer Center, New York, NY 2011
Residency, Internal Medicine: Massachusetts General Hospital, Boston, MA 2006
PhD, Immunology: University of Texas Southwestern Medical School, Dallas, TX 2004
Medical Degree: University of Texas Southwestern Medical School, Dallas, TX 2004
BA, Molecular Biology: Northwestern University, Evanston, IL 1996

Publication & Research

Publication & Research

Bladder-cancer-associated mutations in <i>RXRA</i> activate peroxisome proliferator-activated receptors to drive urothelial proliferation.
Halstead AM, Kapadia CD, Bolzenius J, Chu CE, Schriefer A, Wartman LD, Bowman GR, Arora VK
Elife. 2017 Nov 16; 6pii: e30862. doi: 10.7554/eLife.30862.

PMID:
    29143738
    [PubMed - indexed for MEDLINE]
Related citations


Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.
Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL
Elife. 2017 Sep 11; 6pii: e27861. doi: 10.7554/eLife.27861.

PMID:
    28891793
    [PubMed - indexed for MEDLINE]
Related citations


Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.
Watson PA, Arora VK, Sawyers CL
Nat Rev Cancer. 2015 Dec; 15(12)701-11. doi: 10.1038/nrc4016.

PMID:
    26563462
    [PubMed - indexed for MEDLINE]
Related citations


Organoid cultures derived from patients with advanced prostate cancer.
Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y
Cell. 2014 Sep 25; 159(1)176-187. doi: 10.1016/j.cell.2014.08.016.

PMID:
    25201530
    [PubMed - indexed for MEDLINE]
Related citations


Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL
Cell. 2013 Dec 5; 155(6)1309-22. doi: 10.1016/j.cell.2013.11.012.

PMID:
    24315100
    [PubMed - indexed for MEDLINE]
Related citations


Androgen receptor signaling regulates DNA repair in prostate cancers.
Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, Goglia AG, Gopalan A, Hieronymus H, Wongvipat J, Scardino PT, Zelefsky MJ, Jasin M, Chaudhuri J, Powell SN, Sawyers CL
Cancer Discov. 2013 Nov; 3(11)1245-53. doi: 10.1158/2159-8290.CD-13-0172.

PMID:
    24027196
    [PubMed - indexed for MEDLINE]
Related citations


Overcoming mutation-based resistance to antiandrogens with rational drug design.
Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL
Elife. 2013 Apr 9; 2e00499. doi: 10.7554/eLife.00499.

PMID:
    23580326
    [PubMed - indexed for MEDLINE]
Related citations


Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL
Cancer Cell. 2011 May 17; 19(5)575-86. doi: 10.1016/j.ccr.2011.04.008.

PMID:
    21575859
    [PubMed - indexed for MEDLINE]
Related citations


Integrative genomic profiling of human prostate cancer.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL
Cancer Cell. 2010 Jul 13; 18(1)11-22. doi: 10.1016/j.ccr.2010.05.026.

PMID:
    20579941
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2017:

Company Name: Oric Pharmaceuticals

Royalties:

Equity: Yes

Consulting/Advisory Board:

Speaker Fees:

Reporting Date: May 01, 2018

Areas of Research Interest

Genitourinary oncology, prostate cancer, bladder cancer